Rating Change
HC Wainwright & Co. analysts reiterated a Buy rating on Climb Bio, Inc. (NASDAQ:CLYM) on June 24, 2026.
reiterateNASDAQ:CLYM
HC Wainwright & Co. Reiterates Buy Rating on Climb Bio, Inc. (CLYM)
Rating Change HC Wainwright & Co. analysts reiterated a Buy rating on Climb Bio, Inc. (NASDAQ:CLYM) on June 24, 2026.
Market Context
Climb Bio, Inc. operates in the Healthcare sector. The stock currently trades at $13.40 with a market capitalization of $157.2M.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Climb Bio, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Climb Bio, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jun 24, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jun 12, 2026 | Wedbush | Outperform | N/A |
| Jun 11, 2026 | BTIG | Buy | N/A |
| Jun 08, 2026 | Guggenheim | Buy | N/A |
| Jun 08, 2026 | BTIG | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View CLYM Stock Page
Frequently Asked Questions
What does a Buy rating mean for CLYM?
A Buy rating from HC Wainwright & Co. reflects the analyst's outlook on Climb Bio, Inc. (NASDAQ:CLYM). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CLYM forecast page.